Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 10/20 | 0.72 |
| ▸ | MME | P08473 | 10/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.50 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.50 |
| ▸ | PRKX | P51817 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.50 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873816 | 1.00 | MMEL1 (0.72) | MMEL1MMEROCK2RPS6KA5RPS6KA4 | |
| SCHEMBL2872587 | 0.86 | MMEL1 (0.55) | MMEL1MMEROCK2RPS6KA5RPS6KA4 | |
| SCHEMBL2872591 | 0.86 | MMEL1 (0.55) | MMEL1MMEROCK2RPS6KA5RPS6KA4 | |
| SCHEMBL18672604 | 0.84 | MME (0.76) | MMEL1MME | |
| SCHEMBL12317270 | 0.84 | MME (0.76) | MMEL1MME | |
| SCHEMBL2877398 | 0.84 | MMEL1 (1.00) | MMEL1MME | |
| SCHEMBL2874749 | 0.83 | MMEL1 (0.81) | MMEL1MME | |
| SCHEMBL2870245 | 0.82 | MMEL1 (0.63) | MMEL1MMECTSA | |
| SCHEMBL2870237 | 0.82 | MMEL1 (0.63) | MMEL1MMECTSA | |
| SCHEMBL2870016 | 0.80 | MMEL1 (0.72) | MMEL1MMEROCK2RPS6KA5RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ROCK2 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.